BRAF and metastatic melanoma: The ESMO-MCBS grade of CHECKMATE-066 [11, 12], which support the approval of nivolumab as first line therapy of BRAF wild-type unresectable or metastatic melanoma increased from 4 to 5 due to improved QOL, which were not available in the primary report [11] and approval documents.